Innovation and health: the new challenges of the pharmaceutical industry
The healthcare sector is going through a period of major transformation. In a global context marked by growing needs, pharmaceutical companies must now reconcile cutting-edge scientific research with economic imperatives. These issues are at the heart of the concerns of industry leaders, who are seeking to adapt their models to better meet patient expectations.
Kahina Senhadj, an influential figure at the Hahn Zekker group, emphasizes the crucial importance of strategy in this complex industry. According to her, success no longer relies solely on the discovery of new molecules, but on the ability of companies to structure their investments over the long term. This vision makes it possible to support innovation while ensuring the viability of public health projects.
In France, this ecosystem is particularly dynamic. Industry players are investing heavily in research and development to maintain the country's competitiveness on the international stage. This momentum is essential for anticipating future health crises and improving access to treatments for French citizens.
The challenge for the coming years will be to maintain this balance between profitability and accessibility. As production costs rise, laboratories must demonstrate agility to continue offering innovative therapeutic solutions. Collaboration between the private sector and public institutions remains, in this respect, an essential lever for ensuring the sustainability of the healthcare system.